DSIP Dosage Chart
Pre-bed subcutaneous protocol, short PRN cycles, and the inconsistent efficacy literature you should know about.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
DSIP (Delta Sleep-Inducing Peptide) was identified in the 1970s in animals undergoing electrically-induced sleep. Early enthusiasm for its sleep-promoting effects was followed by inconsistent clinical results — efficacy data has been variable and DSIP has never reached approved therapeutic status. It remains in use through compounding pharmacies as a sleep adjunct.
No dosing table is shown for DSIP
Every citation previously listed on this chart was checked against PubMed and PMC and none of them resolved to the paper claimed; all were removed. That leaves no verifiable peer-reviewed source behind the doses below. The protocols shown are clinic and vendor convention only. Treat every number here as unverified practice, not established dosing, and do not use it without a clinician who can justify it independently.
Rather than publish doses we cannot support, we have withheld them. If you are considering DSIP, that absence of evidence is itself the most useful thing this page can tell you — take it to a clinician.
Where these numbers come from
Every citation previously listed on this chart was checked against PubMed and PMC and none of them resolved to the paper claimed; all were removed. That leaves no verifiable peer-reviewed source behind the doses below. The protocols shown are clinic and vendor convention only. Treat every number here as unverified practice, not established dosing, and do not use it without a clinician who can justify it independently.
DSIP has minimal reported acute toxicity, but its inconsistent efficacy means many users see little benefit.
- •Reported side effects in practice are minimal — injection-site reactions are the most common.
- •Inconsistent efficacy data — many users report no noticeable sleep effect.
- •Long-term safety beyond short PRN courses is not well-characterized.
- •Not FDA-approved.
- •Pregnancy or breastfeeding
DSIP Dosing FAQ
Published efficacy data is inconsistent. Some users report improved sleep onset and quality; others report no effect. If you're considering DSIP, set expectations for variability — and consider that simpler interventions (sleep hygiene, melatonin, behavioral therapy for insomnia) have stronger evidence.
Most protocols specify 30–60 minutes pre-bed. Subcutaneous injection in the abdomen or thigh.
Continuous nightly use is not the standard protocol — most practitioners suggest PRN dosing in 1–2 week courses with breaks. Continuous long-term use has not been well-studied.
Related Dosage Charts
Want the full DSIP guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for DSIP therapy.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.